PDF(Pubmed)
Abstract：
To observe the clinical outcomes of patients diagnosed with metastatic breast cancer undergoing Trastuzumab Deruxtecan (T-DXd) therapy in a real-world setting. The study retrospectively reviewed and collected medical data from 13 patients at Shin Kong Wu Ho-Su Memorial Hospital who underwent T-DXd treatment over a period from April 2022 to June 2023. Demographics, pathological characteristics, treatment patterns, and outcomes were descriptively analyzed. Thirteen patients diagnosed with metastatic breast cancer underwent T-DXd treatment between April 2022 and June 2023. This study observed that T-DXd was effective in patients with high human epidermal growth factor receptor 2 (HER2) levels. In patients with low HER2, the majority also experienced favorable responses. Only 2 patients exhibited poor or no response: one was a BRCA2 carrier with unmanageable disease progression, and the other had a HER2 1 + status with multiorgan metastases whose cancer was not controlled by T-DXd. Additionally, 2 patients with no HER2 expression responded well to T-DXd treatment. T-DXd is a valuable treatment alternative for patients with breast cancer, including those with HER2-high, HER2-low, and HER2-negative statuses. In this study, the majority of patients experienced positive therapeutic effects. However, this evaluation relied on a limited sample size and short-term observations. Additional studies involving larger and more diverse patient groups and long follow-up durations are required.
摘要：
观察接受曲妥珠单抗Deruxtecan（T-DXd）治疗的转移性乳腺癌患者的临床疗效。该研究回顾性地回顾并收集了在2022年4月至2023年6月期间接受T-DXd治疗的新光乌和苏纪念医院13名患者的医疗数据。人口统计,病理特征，治疗模式,和结果进行描述性分析。在2022年4月至2023年6月之间，13例诊断为转移性乳腺癌的患者接受了T-DXd治疗。这项研究观察到T-DXd在人表皮生长因子受体2（HER2）水平高的患者中有效。在低HER2患者中，大多数也经历了良好的反应。只有2名患者表现出不良或无反应：其中一名是BRCA2携带者，疾病进展难以控制，另一个具有HER21+状态，多器官转移，其癌症不受T-DXd控制。此外,2例无HER2表达的患者对T-DXd治疗反应良好。T-DXd是乳腺癌患者的一种有价值的治疗方法，包括那些HER2高的，HER2低，和HER2阴性状态。在这项研究中,大多数患者经历了积极的治疗效果。然而,这项评估依赖于有限的样本量和短期观察.需要涉及更大和更多样化的患者群体和长期随访的其他研究。
